ITOS Form 4: Options Canceled for Cash and CVRs After Merger
Rhea-AI Filing Summary
Lee David K, a director of iTeos Therapeutics, Inc. (ITOS), reported transactions dated 08/29/2025 related to company stock options in connection with the merger of the company with Concentra Merger Sub VIII, Inc. The filing notes two option entries showing dispositions: 21,141 and 23,625 stock options with an exercise price of $9.84 that were reported as disposed. The Form 4 explains that, under the Merger Agreement, outstanding unvested options tied to certain service or severance arrangements became immediately vested and exercisable, while in-the-money options with exercise prices below the cash consideration per share of $10.047 were canceled in exchange for cash consideration and contractual contingent value rights.
Positive
- Accelerated vesting for eligible unvested options occurred, making those awards immediately exercisable as described in the Merger Agreement
- Cash consideration was provided for canceled in-the-money options, ensuring immediate cash value to option holders
Negative
- In-the-money options were canceled rather than preserved, removing potential future upside tied to the company as an independent public entity
- Reported dispositions total 44,766 options which could affect post-transaction equity interests and beneficial ownership disclosures
Insights
TL;DR: Form 4 shows merger-driven option accelerations and cancellations that convert option value into immediate cash and contingent value rights, a routine merger outcome.
The filing documents option dispositions tied directly to the Merger Agreement. Two option lots totaling 44,766 options are reported as disposed and reflect the standardized treatment where in-the-money options were canceled for cash consideration and CVRs while certain awards accelerated and became exercisable. For investors, this is a mechanical equity-treatment event rather than an operational development; it clarifies dilution and immediate cash payouts to option holders.
TL;DR: Disclosure details equity award treatment on change of control: accelerated vesting for eligible awards and cancellation-for-cash for in-the-money options.
The Form 4 provides transparent mapping of how the Compensation and Leadership Development Committee implemented the Merger Agreement provisions. It confirms accelerated vesting for awards subject to specified employment or severance arrangements and the contractual mechanism that converted in-the-money options into cash and contingent value rights, which is consistent with typical M&A equity settlement practices.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 21,141 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 23,625 | $0.00 | -- |
Footnotes (1)
- This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). Pursuant to the actions of the of the Compensation and Leadership Development Committee of the Board of Directors of the Company and in accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") (Continued from footnote 1) that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full. In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the $10.047 in cash per share ("Cash Amount") (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.
